[Reprinted] The seventh batch of national minions is imminent, and the three changes you have to pay attention to

[Reprinted] The seventh batch of national minions is imminent, and the three changes you have to pay attention to

Source: amino observation/Fang Taozhi

The seventh batch of national collection that makes many pharmaceutical companies love and hate, as expected.

On June 20, Shanghai Sunshine Pharmaceutical Procurement Network released the seventh batch of collection documents "National Pharmaceutical Collection Purchasing Documents". The document mentioned that this time will be opened in Shanghai on July 12.

However, according to the latest news from Shanghai Sunshine Pharmaceutical Purchasing Network on June 27, information such as the seventh batch of national collection application materials was changed.

The focus is that the location of the application materials is no longer Shanghai, but the Nanjing Zijin Village Convention Center; Watch directly.

In addition to these two changes, what changes have the seventh batch of national minions compared with the rules of the previous national collection? Let's take a look together.

/ 01 /

more competitive,

A "blood battle" is about

The procurement variety catalogs show that this time the national optical collection involves 61 varieties and 125 specifications. Among these 61 varieties, at least 13 varieties of competitive manufacturers are not less than 10, and large varieties of over 1 billion include more than ten species such as omeprazole, ortololol, and azolic acid.

Among them, the most competitive varieties are olprazole sodium in injection. In 2020, the sales scale of Omertazole sodium in the domestic medical market reached 5.21 billion yuan. This time, 28 pharmaceutical companies, including the original research companies, participated in the competition of this variety.

Followed by Kylinin phosphate injection. In 2020, the total sales of Kylinophenoico phosphate injections in the domestic medical market were 309 million yuan. This time, 18 companies including North China Pharmaceuticals, China Resources Shuanghe, Xinhua, Shandong, and 18 companies including the competition are not fierce.

From the perspective of admission pharmaceutical companies, nearly 300 companies have met the application conditions.

In the local enterprises, five companies including Qilu Pharmaceutical, Caren Pharmaceutical, Yangzi Jiang Pharmaceutical, Stone Pharmaceutical Group, and Chengdu Bite all have more than 10 products in the seventh batch of national mining, of which Qilu Pharmaceuticals are the most qualified varieties There are 17 models.

Among the multinational pharmaceutical companies, Pfizer ranked first in five medicines, namely metamorite nylon (oral release agent), methadonin nylon (injection), Schonidinib (oral interpretation), and elassee (injection agent (injection agent) ) And Ilidekang (injection); followed by Novartis and Roche, both were shortlisted for 4 medicines.

In accordance with the seventh batch of national mining rules, if the actual number of enterprises who apply for enterprises is more than 13 or more, the maximum number of shortlisted enterprises can reach 10; if the actual number of enterprises who apply for the enterprise is 12 or more, the maximum number of shortlisted companies can reach 9. Essence

It seems that the seventh batch of National Cai will start a "bloody storm".

/ 02 /

Price competition upgrade,

Election rules are stricter

Among the seventh batch of national optics, the conditions for selected by enterprises have become more stringent.

In the national collection last year, the selection of conditions after the company was shortlisted only to meet one of the three sets of conditions:

The unit comparable price is 1.8 times the comparable price of the minimum unit of the same variety

The unit's declaration price has dropped by more than half, and the unit comparable price is less than 0.1 yuan.

And this year, the company wants to be selected, which must meet the previous conditions, but also meet the following new conditions:

After meeting the above three conditions, the highest level in the same variety.

After meeting the above three conditions, the same variety is the highest level. According to the "comparable price of the highest level 'unit'/minimum level of the same variety 'units' units" calculation ratio, the ratio of the ratio As a result, the top 6 of China and Africa were arranged. If the ratio is equal to the 6th place, it is tied for 6th place.

Simply put, when the enterprise meets the two conditions, it is necessary to meet the highest quotation.

If the highest quotation of the same variety, the ratio of the minimum quotation of the quotation to the same variety is sorted from high to low, and companies that are sixth after the sixth place can be selected.

/ 03 /

Coperly disconnect,

New "substitute" policy

In response to the frequent confession phenomenon that appeared before, this national collection also gives a response plan, adding an alternative mechanism.

According to the selection position, the proposed enterprises need to choose the main region in turn, and the confirmation of the main supply area is consistent with the fifth batch of national collection. Each of the regions of each proposed company must be different from its main region.

The point of change is that after confirming the main supply area, you need to choose a provisional area. In the preparation area, it becomes a candidate enterprise, and it is necessary to choose the main supply area of ​​the enterprise and the preparation area. If there are only one company who is selected in China, there is no need to participate in the regional confirmation.

The provision area is consistent with the confirmation process of the main region, but each proposed enterprise can only choose its preparation area from the main region of other proposed enterprises.

When the main supply enterprise cannot meet the market demand of the selected areas, the preparation enterprise can obtain the owner's identity in accordance with the relevant procedures. If the confirmed candidate enterprises cannot meet the supply needs, the province may start the supply process of supplementary candidates, and the additional candidate enterprises that are supplemented will be determined from other Chinese selected enterprises.

At the same time, the document stipulates that if the enterprise is intended to be selected by any province, if it is rated as "serious" or "particularly serious" in accordance with the medical price and recruitment credit evaluation system, or in two yearsIf the selection variety is eligible for the eligibility of the selection of the second election office, in the confirmation of the main supply and preparation areas, neither has the qualifications for the first selection of the selected enterprises to confirm the region for the first time.This has once again strengthened the punishment mechanism for disconnected enterprises.

For pharmaceutical companies, not only need to consider the amount of the main region, but also the number of reporting regions, this also requires companies to make a more rigorous amount in this report.

Disclaimer: This article is the content of Yaozhi.com, and the copyright of the pictures and text belongs to the original author. The purpose of reprinting is to pass more information, which does not represent the viewpoint of this platform.If the content, copyright and other issues are involved in the work, please leave a message on this platform, and we will delete it as soon as possible.

- END -